Guidelines for Perioperative Medication Continuity: Evidence-Based Recommendations for Clinical Practice

Abstract

Perioperative medication management remains a critical aspect of patient safety, influencing surgical outcomes and overall morbidity. This review synthesizes recent guideline-based evidence regarding perioperative medication continuity, focusing on prevalent drug classes, risk assessment, and tailored strategies for minimizing adverse events. By integrating pathophysiological considerations, risk stratification, and evolving recommendations, this article aims to equip healthcare professionals with actionable insights for optimizing perioperative pharmacotherapy.

Introduction

The perioperative phase imposes unique challenges in the management of chronic medications, necessitating an individualized approach rooted in current evidence and clinical guidelines. Discontinuation or inappropriate continuation of therapy during this period can result in significant complications, from withdrawal syndromes to increased risk of thromboembolic or cardiovascular events. As surgical volumes and patient complexity rise globally, the imperative to standardize perioperative medication protocols has never been greater. This article provides a comprehensive overview, from underlying mechanisms to practical recommendations, for perioperative medication continuity.

Epidemiology / Disease Burden

Globally, an estimated 313 million surgical procedures are performed annually, and a significant proportion of patients present with chronic comorbidities requiring ongoing pharmacotherapy. Polypharmacy is prevalent, especially among the elderly, with studies indicating that over 50% of surgical patients are on at least five medications. Inappropriate perioperative medication management is associated with increased hospital length of stay, postoperative complications, and readmissions, contributing to substantial healthcare costs and patient morbidity.

Pathophysiology

The perioperative state is characterized by physiological stress, hemodynamic fluctuations, and altered pharmacokinetics due to anesthesia, fluid shifts, and organ dysfunction. These changes can unmask or exacerbate the risks posed by medication withdrawal or toxicity. For instance, abrupt cessation of beta-blockers can provoke rebound hypertension and arrhythmias, while continued use of anticoagulants without risk stratification may predispose to perioperative bleeding. Understanding drug-specific mechanisms and their interactions with surgical stress is vital for informed medication management.

Risk Factors

Several factors modulate the risks associated with perioperative medication decisions. Patient-related variables include age, comorbidities (cardiovascular, renal, hepatic, endocrine), and history of medication dependence. Surgery-related risks encompass type, urgency, and anticipated bleeding risk. Polypharmacy, poor preoperative medication reconciliation, and lack of standardized protocols further heighten the potential for adverse outcomes.

Clinical Features

Clinical manifestations of inappropriate perioperative medication management are diverse. Withdrawal of antihypertensives may result in hypertensive crises; omission of anticonvulsants can trigger seizures; and discontinuation of corticosteroids may precipitate adrenal insufficiency. Conversely, continuation of certain agents such as antiplatelets or oral hypoglycemics can lead to hemorrhagic or hypoglycemic complications, respectively. Recognition of at-risk patients and early identification of adverse events are crucial for optimal outcomes.

Diagnosis

Preoperative medication review forms the cornerstone of diagnosis. Comprehensive medication reconciliation, involving verification of all current drugs—including over-the-counter and herbal supplements—is essential. Clinical assessment should focus on potential for withdrawal, drug interactions, and organ-specific effects. Laboratory investigations, such as renal and hepatic function tests, coagulation profiles, and blood glucose monitoring, provide additional risk stratification to guide perioperative decision-making.

Treatment & Management

Perioperative medication management is inherently patient-specific. General principles include continuation of essential medications (e.g., beta-blockers, statins, antiepileptics), temporary modification or cessation of drugs with high risk for perioperative complications (e.g., ACE inhibitors, ARBs, certain anticoagulants), and bridging strategies where appropriate (e.g., low molecular weight heparin for high-risk atrial fibrillation). Multidisciplinary collaboration between anesthesiologists, surgeons, pharmacists, and primary care teams is fundamental in developing individualized management plans, ensuring seamless communication and patient safety.

Recent Advances / Emerging Therapies

Recent advances have focused on risk stratification tools and digital health platforms to optimize perioperative medication management. Clinical decision support systems integrated into electronic health records now provide alerts for high-risk medications. Guideline updates increasingly emphasize the use of direct oral anticoagulants (DOACs) and newer antiplatelet agents, necessitating revised protocols for perioperative management. Pharmacogenomics is emerging as a tool to predict patient-specific drug responses, although its application in perioperative care remains investigational.

Guideline Recommendations

Major guidelines, including those from the American College of Cardiology, American Society of Anesthesiologists, and European Society of Anaesthesiology, advocate for tailored approaches based on drug class, surgical risk, and patient comorbidities. Key recommendations include: continuation of beta-blockers in patients already on therapy; holding ACE inhibitors and ARBs on the day of surgery unless otherwise indicated; individualized assessment for anticoagulant interruption with consideration of bridging; and continuation of statins for cardiovascular risk reduction. Clear documentation and patient education regarding perioperative medication plans are strongly encouraged.

Conclusion

Perioperative medication continuity is a complex, high-stakes aspect of surgical care that demands a nuanced, evidence-based approach. Recent advances and updated guidelines underscore the importance of individualized risk stratification, multidisciplinary collaboration, and robust preoperative assessment. By adhering to best practices and leveraging emerging technologies, healthcare teams can significantly reduce perioperative morbidity and optimize surgical outcomes for diverse patient populations.